Cargando…

Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review

The availability of all oral direct acting antiviral agents (DAAs) has revolutionized the management of HCV infections in recent years, allowing to achieve a sustained virological response (SVR) in more than 95% of cases, irrespective of hepatitis C Virus (HCV) genotype or staging of liver disease....

Descripción completa

Detalles Bibliográficos
Autores principales:	Onorato, Lorenzo, Pisaturo, Mariantonietta, Starace, Mario, Minichini, Carmine, Di Fraia, Alessandra, Astorri, Roberta, Coppola, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000640/ https://www.ncbi.nlm.nih.gov/pubmed/33800289 http://dx.doi.org/10.3390/v13030432

Ejemplares similares

Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review
por: Russo, Antonio, et al.
Publicado: (2020)

Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma
por: Pisaturo, Mariantonietta, et al.
Publicado: (2021)

Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features
por: Coppola, Nicola, et al.
Publicado: (2017)

Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
por: Calò, Federica, et al.
Publicado: (2022)

Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study
por: Pisaturo, Mariantonietta, et al.
Publicado: (2022)

Correction: Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study
por: Pisaturo, Mariantonietta, et al.
Publicado: (2023)

Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study
por: Coppola, Nicola, et al.
Publicado: (2016)

Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease †
por: Alessio, Loredana, et al.
Publicado: (2022)

Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy
por: Alessio, Loredana, et al.
Publicado: (2018)

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis
por: Mariantonietta, Pisaturo, et al.
Publicado: (2019)

Assessment and Comparison of Two Serological Approaches for the Surveillance of Health Workers Exposed to SARS-CoV-2
por: Russo, Antonio, et al.
Publicado: (2020)

Epidemiology and management of hepatitis C virus infections in immigrant populations
por: Coppola, Nicola, et al.
Publicado: (2019)

Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
por: Onorato, Lorenzo, et al.
Publicado: (2021)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
por: Messina, Vincenzo, et al.
Publicado: (2020)

Correlation Between the Hepatic Expression of Human MicroRNA hsa-miR-125a-5p and the Progression of Fibrosis in Patients With Overt and Occult HBV Infection
por: Coppola, Nicola, et al.
Publicado: (2018)

Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf
por: Coppola, Nicola, et al.
Publicado: (2017)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
por: Sagnelli, Evangelista, et al.
Publicado: (2012)

HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation
por: Piermatteo, Lorenzo, et al.
Publicado: (2021)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
por: Scaglione, Vincenzo, et al.
Publicado: (2020)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients
por: Salmon, Dominique, et al.
Publicado: (2018)

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)
por: Pisaturo, Mariantonietta, et al.
Publicado: (2019)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention
por: Sagnelli, Caterina, et al.
Publicado: (2019)

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
por: Sagnelli, Caterina, et al.
Publicado: (2021)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review
por: Onorato, Lorenzo, et al.
Publicado: (2022)

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2020)

Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2012)

Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic
por: Sagnelli, Caterina, et al.
Publicado: (2021)

Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis
por: Mangia, Alessandra, et al.
Publicado: (2018)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
por: Fagiuoli, Stefano, et al.
Publicado: (2023)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gltin8sbmuo0hlf9pab8io5092